-

Onego Bio Launches “The Power of Trichoderma reesei” Series to Showcase Innovation, Scale, and Real-World Applications

HELSINKI--(BUSINESS WIRE)--Onego Bio, a food ingredient company producing non-animal egg protein with precision fermentation*, today announced the launch of a new expert series titled “The Power of Trichoderma reesei: Building the Future with Fungi.” This multi-part initiative reveals the full potential of Trichoderma reesei, the microbial platform behind Onego’s Bioalbumen®, by spotlighting its scientific strengths, industrial scale, and practical performance across food manufacturing.

The first session, “Why Trichoderma reesei is Precision Fermentation’s Quiet Workhorse,” will be held on December 18, 2025, featuring Dr. Sharief Barends, Head of Research Leiden (Netherlands) and Head of Fungal Genetics at IFF, and Dr. Christopher Landowski, Co-Founder and Chief Technology Officer at Onego Bio. Together, they will explore the research legacy, strengths, and industrial advantages of T. reesei, and how it compares to other microbial platforms commonly used in precision fermentation. A white paper will follow, offering further insight into its unique capabilities in protein manufacturing.

Following this first session, the series will continue with additional topics ranging from manufacturing to market economics to food application, including:

  • A second session, slated for January, that will feature Dr. Marshall Bredwell, Chief Operating Officer at Perfect Day and former process and manufacturing leader at Novozymes in both the US and China, alongside Onego Bio Head of Manufacturing, Arni Kujala and focus on advantages of the T. reesei platform in manufacturing and scale-up of proteins and commodity ingredients.
  • A third session, slated for February, on market economics and supply chain resiliency, with Onego Chief Financial Officer, Tom Ferguson, and an industry expert
  • A fourth session, slated for March, in which the series will culminate in a live cooking demonstration showcasing Bioalbumen®, Onego’s non-animal egg protein. This session will spotlight the impact of real-world functionality, from whipping and binding to emulsification, demonstrating how bioidentical ingredients can deliver consistency, versatility, and culinary excellence.

“This series is about shining a light on the platform at the heart of scalable protein innovation,” said Maija Itkonen, Co-Founder and CEO of Onego Bio. “Trichoderma reesei has quietly powered industries for decades, but its full potential in food is still underappreciated. We believe it’s one of the most efficient and underleveraged tools in the fermentation toolbox, and it’s time the world saw what it can do for food.”

The Power of Trichoderma reesei series is part of Onego Bio’s broader mission to foster ecosystem collaboration, provide clarity and transparency into innovation, and advance a resilient future for sustainable protein.

To register for this series, please use this registration form or visit https://tinyurl.com/bde6xzcf.

About Onego Bio

Onego Bio is a food ingredient company on a mission to create a more resilient food system through its product Bioalbumen®: the first non-animal egg protein with an amino acid sequence identical to the natural protein. Made through precision fermentation, Bioalbumen® matches the taste, nutrition, and functionality of the main protein from traditional eggs with an environmental impact around 90% smaller. Its unmatched versatility makes it ideal across a wide range of applications, while providing cost and supply stability for food manufacturers. Learn more at www.onego.bio

* Bioalbumen® is an egg protein produced from non-animal sources using precision fermentation. Instead of using chickens, a microorganism is fed sugar in large fermentation tanks and produces ovalbumin: the main protein in egg whites. The protein is then purified and dried into a powder.

Contacts

For media inquires, please contact press@onego.bio

Onego Bio



Contacts

For media inquires, please contact press@onego.bio

More News From Onego Bio

Onego Bio Receives FDA “No Questions” Letter on GRAS Status of Bioalbumen®

SAN DIEGO--(BUSINESS WIRE)--Onego Bio, a food ingredient company producing egg protein through precision fermentation, announced today that the U.S. Food and Drug Administration (FDA) has issued a “no questions” letter regarding the company’s conclusion that its flagship product, marketed as Bioalbumen®, is Generally Recognized As Safe (GRAS) under its conditions of use in a wide range of food and beverage applications. The FDA’s decision, communicated in response to GRAS Notice No. GRN 1249, c...

Onego Bio Chooses Jefferson County, Wisconsin for Flagship Egg Protein Manufacturing Facility

JEFFERSON COUNTY, Wis.--(BUSINESS WIRE)--Onego Bio, a food ingredient company producing egg protein powder through fermentation, will become the second tenant at Jefferson County’s Food and Beverage Innovation Campus. The $777,000 purchase of 25.9 acres within the campus located on the south side of the City of Jefferson was approved by the Jefferson County Board of Supervisors at its December meeting. The proposed Jefferson site will be Onego Bio’s flagship manufacturing facility, dedicated to...

Onego Bio Submits Formal GRAS Notification to FDA for Bioalbumen®

SAN DIEGO--(BUSINESS WIRE)--Onego Bio, a Finnish-U.S. food ingredient company, announced the submission of its Generally Recognized as Safe (GRAS) notification to the U.S. Food and Drug Administration (FDA) for its non-animal ovalbumin, produced through precision fermentation using Trichoderma reesei, and branded as Bioalbumen®. This milestone marks a critical step toward bringing the first non-animal egg protein with an amino acid sequence identical to the natural protein, to the global food m...
Back to Newsroom